AT

Atavistik Bio is a preclinical-stage biotechnology company focused on discovering the next generation of precision small molecule therapeutics by leveraging the power of metabolite-protein interactions. The company utilizes its proprietary AMPS (Atavistik Metabolite-Protein Screening) platform to identify novel allosteric binding sites that are naturally regulated by metabolites, enabling the targeting of proteins previously considered undruggable. By integrating high-throughput screening with advanced structural biology and computational chemistry, Atavistik Bio aims to develop transformative medicines for patients with metabolic diseases and cancer. The company's approach seeks to restore physiological balance by modulating key regulatory nodes in metabolic pathways.